Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study

Basso-Valentina, Francesca; Canzonieri, Vincenzo; De Cecio, Rossella; Arenare, Laura; Lorusso, Domenica; Cecere, Sabrina Chiara; Pivetta, Eliana; Russo, Daniela; Di Mauro, Annabella; Artioli, Grazia; Spina, Anna; De Angelis, Carmine; Califano, Daniela; Cinieri, Saverio; Scognamiglio, Giosuè; Salutari, Vanda; Chiodini, Paolo; Perrone, Francesco; Pignata, Sandro; Baldassarre, Gustavo

doi:10.1002/ctm2.70373

We are pleased to present our latest analyses, showing that multiple immunofluorescence (MIF) can be used in large multicenter clinical trials to define the prognostic/predictive value of programmed death-ligand 1 (PD-L1) by concomitantly and precisely assessing its expression and spatial distribution in the tumour tissue, outperforming classical immunohistochemistry (IHC).

Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study / Basso-Valentina, F., Canzonieri, V., De Cecio, R., Arenare, L., Lorusso, D., Cecere, S.C., Pivetta, E., Russo, D., Di Mauro, A., Artioli, G., Spina, A., De Angelis, C., Califano, D., Cinieri, S., Scognamiglio, G., Salutari, V., Chiodini, P., Perrone, F., Pignata, S., Baldassarre, G.. - In: CLINICAL AND TRANSLATIONAL MEDICINE. - ISSN 2001-1326. - ELETTRONICO. - 15:6(2025), pp. e70373."-"-e70373."-". [10.1002/ctm2.70373]